Trial document
DRKS00018695
Trial Description
Title
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE), AIO-KRK-0217
Trial Acronym
CIRCULATE
URL of the Trial
[---]*
Brief Summary in Lay Language
The primary aim of the CIRCULATE study is to compare the disease free survival in patients with colon cancer stage II who are positive for postoperative circulating tumour DNA with vs. without chemotherapy.
Brief Summary in Scientific Language
The primary aim of the CIRCULATE study is to compare the disease free survival (DSF) in patients with colon cancer stage II who are positive for postoperative circulating tumour DNA with vs. without capecitabine.
Do you plan to share individual participant data with other researchers?
No
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00018695
- 2019/12/09
- [---]*
- yes
- Approved
- EK-407092019, Ethikkommission der Medizinischen Fakultät der Technischen Universität Dresden
Secondary IDs
- 2018-003691-12
Health Condition or Problem studied
- Colon cancer stage II
- Rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum )
- C18 - Malignant neoplasm of colon
- C19 - Malignant neoplasm of rectosigmoid junction
- C20 - Malignant neoplasm of rectum
Interventions/Observational Groups
-
Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months)
Capecitabine, if combined with oxaliplatin:
Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)]
Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days).
Treatment duration: 4 or 8 cycles (approx. 3 or 6 months) - no Chemotherapie, follw-up
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Open (masking not used)
- [---]*
- Control group receives no treatment
- Treatment
- Parallel
- III
- N/A
Primary Outcome
Disease free survival of ctDNA positive patients randomised to "chemotherapy" vs. "follow-up", measured from randomisation to any recurrence, metastasis, second colorectal or non colorectal cancer and death from any cause. The primary endpoint will be tested in all randomised ctDNA positive patients and be evaluated by a stratified log rank test.
Interims Analysis will be made after 93 events (approx. 38 months after study start), final analysis for the primary endpoint after 154 events (approx. 60 months after study start).
Secondary Outcome
a) Overall survival in ctDNApos patients with adjuvant therapy vs follow-up, measured from randomisation to death from any cause, in all
randomised ctDNA positive patients and be evaluated by a stratified log rank test.
b) Disease free survival in ctDNAneg patients randomised to follow up (rate of patients disease free and alive 3 years after randomisation according to Kaplan-Meier estimation with 95% CI, intention-to-treat
analysis). Any recurrence, metastasis, second colorectal or non-colorectal cancer and death from any cause is regarded as event
c) Overall survival in ctDNAneg patients randomised to "follow up" (rate of patients alive after 5 years after randomisation according to Kaplan-Meier estimation with 95% CI)
d) Disease free and overall survival of ctDNApos vs. ctDNAneg patients randomized to „follow-up" (measured from randomisation to the event
in an intention-to-treat analysis by stratified log rank test). Any recurrence, metastasis, second colorectal or non-colorectal cancer and death from any cause are regarded as event for DFS. Death of any cause will be regarded as event for overall survival.
e) Site of metastases (lymph node vs. peritoneal/local recurrence vs other) in ctDNApos vs. ctDNAneg patients who have a recurrence / metastases
f) Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy (descriptive analysis for patients randomised to
"chemotherapy" who have received at least one dose of chemotherapy).
Countries of Recruitment
- Germany
- Austria
Locations of Recruitment
- Medical Center
- University Medical Center
- Doctor's Practice
Recruitment
- Actual
- 2020/06/26
- 4812
- Multicenter trial
- International
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
Inclusion criteria for screening phase:
1) Resected colon cancer stage II,
OR
Resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum ), so that the treatment follows the recommendations for colon cancer. Patients, in whom the tumour stage is not yet know, can be enrolled into the screening.
2) Signed informed consent for the screening Phase
Inclusion criteria for the randomised phase:
1) Resected colon cancer stage II,
OR resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum), so that the treatment follows the recommendations for colon
cancer.
2) Known microsatellite or mismatch repair status
3) Confirmation, that the ctDNA result is available
4) Signed second informed consent (for the randomised phase)
Exclusion Criteria
Exclusion criteria for Screening:
1) Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
2) Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
3) Patients, who have an obvious contra-indication for adjuvant chemotherapy (i.e. due to the performance status, comorbidity, active second cancer or age). It should be considered that patients with an age of more than 75 years frequently not fulfil criteria for adjuvant chemotherapy.
4) R1- or R2-status (patients with [still] unknown R-status can be screened)
5) Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
6) Age < 18 years
7) Pregnant or breast feeding patients
Exclusion criteria for randomised phase:
1) Patients with microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
2) Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
3) R1- or R2- status, or unknown R- status (Rx)
4) Number of investigated lymph nodes < 10
5) WHO performance status ≥ 2
6) Colon or rectal cancer with UICC stage III or IV
7) Second cancer, except
a. simultaneous or metachronous colon or rectal cancer with UICC stage ≤ I,
b. curatively treated basal cell carcinoma or squamous cell carcinoma of the skin and in-situ cervical carcinoma
c. tumours with a disease free survival of more than five years
8) Contra indications for chemotherapy, especially:
a. Leukocytes < 3,0 Gpt/l
b. Neutrophil granulocytes < 1,5 Gpt/l
c. Thrombocytes < 100 Gpt/l
d. ALAT or ASAT > 3 x ULN
e. Creatinine clearance (calculated according Cockcroft-Gault) < 30 ml/min
9) Comorbidities relevantly interfering with the prognosis of the patients, i.e.:
a. heart insufficiency NYHA III/IV
b. relevant coronary heart disease,
c. Diabetes mellitus with late sequelae
10) Organ, stem cell or bone marrow transplantation
11) Known hypersensitivity to capecitabine
In case of known hypersensitivity to oxaliplatin, the patients can participate, but not receive oxaliplatin
12) Medication with brivudine, sorivudine or analogues in the last four weeks before planned treatment start
13) Known biallelic or homozygous dihydropyrimidine dehydrogenase (DPD)-deficiency
14) Acute infections
15) Known HIV- infections, known active hepatitis B or C-infection
16) Participation at another interventional study for medical treatment during the last four weeks before randomisation
17) Neoadjuvant therapy before resection
18) Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
19) Age < 18 years
20) Pregnant or breast feeding patients
21) Women of childbearing potential and men with partner with childbearing potential who are not willing to take appropriate precautions to avoid pregnancy with a highly effective method
in case they are randomised to “chemotherapy”
Addresses
-
start of 1:1-Block address primary-sponsor
- Technische Universität Dresden
- 01062 Dresden
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Medizinische Fakultät Carl Gustav Carus der TU Dresden, Medizinische Klinik und Poliklinik I
- Mr. Prof. Dr. med. Gunnar Folprecht
- Fetscherstr. 74
- 01307 Dresden
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- +49351 458 4794
- +49351 458 884794
- gunnar.folprecht at ukdd.de
- https://www.uniklinikum-dresden.de/de/das-klinikum/kliniken-polikliniken-institute/mk1/onkologie
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Medizinische Fakultät Carl Gustav Carus der TU Dresden, Medizinische Klinik und Poliklinik I
- Ms. Marina Lindauer
- Fetscherstr. 74
- 01307 Dresden
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- +49351 458 4824
- +49351 458 887666
- circulate-study at ukdd.de
- https://www.uniklinikum-dresden.de/de/das-klinikum/kliniken-polikliniken-institute/mk1/onkologie
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bundesinstitut für Arzneimittel und Medizinprodukte
- Kurt-Georg-Kiesinger-Allee 3
- 53175 Bonn
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- http://www.bfarm.de/cln_103/DE/Home/home_node.html
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
- [---]*
- [---]*
- [---]*
- [---]*